Microbiology SpectrumMicrobiologyPeer-reviewed journal article
Discordance in Genotypic and Phenotypic anti-tuberculosis drug susceptibility results: time to reconsider critical concentration.
Arti ShrivasiD, Sarman SinghiD, Jitendra SinghiD, Prem ShankariD, Payal Soni, Syed Beenish RufaiiD, Anand Kumar MauryaiD, Shashank PurwariD
Abstract
ObjectiveTo correlate rpoB mutations found on the sanger sequencing in Mycobacterium tuberculosis (MTB) isolates with Minimum Inhibitory Concentrations (MICs) to the rifampicin. MethodsWe assessed the minimum inhibitory concentrations (MICs) for 151 archived clinical MTB isolates that were determined phenotypically susceptible to RIF (101;66.89%) and remaining fifty (50;33.11%) were resistant to RIF by BACTEC MGIT SIRE DST. MIC values were determined using colorimetric redox indicator (Resazurin/REMA) method and results were correlated with rpoB gene mutations associate with rifampicin resistance found. ResultsComparing the MIC and critical concentration, we found that 15 of these 101 (14.85%) isolates were misclassified by MGIT-960 as sensitive at standard critical concentration (1.0{micro}g/mL) though these were found to have low-level RIF resistance by CRI assay (MIC 0.50{micro}g/mL to 1.0{micro}g/mL) and sanger sequencing. We found that all of 15 isolates contained non-synonymous mutations, the commonest being the Ile572Phe (7, 46.66%), followed by Leu533Pro (3, 20.0%), His526Leu (2, 13.33%), His526Asn+Ile572Phe (1), Asp516Tyr (1), and Leu533Pro+Pro564Arg (1). These mutations are reported to confer low-level RIF resistance. But we did not find any mutation at MIC <0.25g/mL. ConclusionWe found that a significant number of MTB isolates have phenotypic and genotypic discordance. Taking 1.0{micro}g/mL of rifampicin as critical concentration, isolates from approximately 15% patients are misidentified as susceptible to rifampicin, even when these strains carry low level drug resistance conferring mutations and have potential to develop clinical MDR-TB.
- Citations
- 8
- FWCI
- 5.11
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rifampicin and rifabutin resistance in 1000 Mycobacterium tuberculosis clinical isolates
M. R. Farhat, J. Sixsmith, … M. Murray·bioRxiv·Sep 25, 2018
- Association between the rifampicin resistance mutations and rifabutin susceptibility in Mycobacterium tuberculosis: a meta-analysis
- Most-probable number based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical M. tuberculosis isolates
S. Vijay, H. N. Nhung, … N. T. T. Thuong·Antimicrobial Agents and ChemotherapyPeer-reviewed·Feb 17, 2021
- Patterns of compensatory mutations in rpoA/B/C genes of multidrug resistant M. tuberculosis in Uganda
David Patrick Kateete, Shakira Namakula, … Moses Lutaakome Joloba·PLoS ONEPeer-reviewed·Dec 4, 2025
- Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates: an in-vitro longitudinal study
V. Srinivasan, N. L. H. Bao, … N. T. Thuong·bioRxiv·Nov 22, 2023
- Novel and Reported Compensatory Mutations in rpoABC Associate Specifically with Predominant Mycobacterium tuberculosis Rifampicin Resistance Marker rpoB:S450L
D. Conkle-Gutierrez, S. M. Ramirez-Busby, … F. Valafar·bioRxiv·Feb 22, 2022